CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 20, 2013-- ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today announced that the U.S. Food and Drug Administration (FDA) has approved revised U.S. Prescribing Information (USPI) and a Risk Evaluation and Mitigation Strategy (REMS) for Iclusig® (ponatinib) that allows immediate resumption of its marketing and commercial distribution. The USPI includes a revised indication statement and boxed warning, updated safety information and recommendations regarding dosing considerations for prescribers.
http://investor.ariad.com/phoenix.zhtml?c=118422&p=irol-newsArticle&ID=1...!